94.61
-0.06 (-0.06%)
| Previous Close | 94.67 |
| Open | 91.00 |
| Volume | 1,278,014 |
| Avg. Volume (3M) | 716,269 |
| Market Cap | 5,591,886,336 |
| Price / Earnings (TTM) | 46.38 |
| Price / Earnings (Forward) | 25.84 |
| Price / Sales | 4.09 |
| Price / Book | 3.92 |
| 52 Weeks Range | |
| Earnings Date | 24 Apr 2025 |
| Profit Margin | 8.81% |
| Operating Margin (TTM) | 11.83% |
| Diluted EPS (TTM) | 2.04 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 57.24% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | 225.16 M |
| Levered Free Cash Flow (TTM) | 168.90 M |
| Return on Assets (TTM) | 4.32% |
| Return on Equity (TTM) | 9.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | Merit Medical Systems, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.50 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.26% |
| % Held by Institutions | 105.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 120.00 (JP Morgan, 26.84%) | Buy |
| Median | 109.00 (15.21%) | |
| Low | 100.00 (Needham, 5.70%) | Buy |
| Average | 109.75 (16.00%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 96.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 25 Apr 2025 | 110.00 (16.27%) | Buy | 94.61 |
| Barrington Research | 25 Apr 2025 | 103.00 (8.87%) | Buy | 94.61 |
| 11 Apr 2025 | 111.00 (17.32%) | Buy | 92.04 | |
| Canaccord Genuity | 25 Apr 2025 | 108.00 (14.15%) | Buy | 94.61 |
| 26 Feb 2025 | 127.00 (34.24%) | Buy | 100.45 | |
| Needham | 25 Apr 2025 | 100.00 (5.70%) | Buy | 94.61 |
| 09 Apr 2025 | 116.00 (22.61%) | Buy | 95.79 | |
| Raymond James | 25 Apr 2025 | 108.00 (14.15%) | Buy | 94.61 |
| Piper Sandler | 23 Apr 2025 | 112.00 (18.38%) | Buy | 93.76 |
| JP Morgan | 28 Mar 2025 | 120.00 (26.84%) | Buy | 103.94 |
| Wells Fargo | 26 Feb 2025 | 117.00 (23.67%) | Buy | 100.45 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance |
| 09 Apr 2025 | Announcement | Merit Medical Launches the Ventrax™ Delivery System |
| 07 Apr 2025 | Announcement | Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025 |
| 27 Mar 2025 | Announcement | Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD |
| 25 Mar 2025 | Announcement | Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) |
| 18 Mar 2025 | Announcement | Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership |
| 10 Mar 2025 | Announcement | First Patient Enrolled in Merit Medical’s PREEMIE Study |
| 25 Feb 2025 | Announcement | Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |